Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: LAIs with longer dosing intervals appear to be associated with improved clinical outcomes and added real-world benefits in the management of schizophrenia. Paliperidone palmitate six-monthly (PP6M) LAI provides the longest dosing interval, twice-yearly dosing, among all currently available LAIs. In clinical trials PP6M was found to be non-inferior in preventing relapses in patients with schizophrenia compared to the three monthly formulation (PP3M) though real world data remain limited. Therefore, the aim of this study was to evaluate the acceptability, effectiveness, and safety of PP6M in patients with schizophrenia in real world practice.

Methods: Data were derived from a naturalistic cohort of patients enrolled in the international, multicenter, prospective Paliperidone-2-per Year (P2Y) study. In this 2-year mirror-image study we compare the number of hospital admissions 1 year pre- and post-PP6M initiation as well as the CGI scores at baseline and the point of each PP6M administration. Discontinuation rates and reasons were also collected.

Results: A total of 201 patients (107 outpatients and 94 chronic long-stay inpatients) were included. The majority of patients had switched to PP6M from either PP3M (76%) or PP1M (19%) while the 3% switched from aripiprazole 1-monthly and the 2% from risperidone-LAI and zuclopenthixol-LAI. The mean CGI-Severity score significantly reduced from baseline to the second and third PP6M administrations in the global cohort (2.31 ± 0.14 . 3.23, p=0.001) as well as in both subgroups. Moreover, the number of hospital admissions decreased from 0.2 ± 0.04 1-year period before to 0.07 ± 0.02 1 year after PP6M initiation (p=0.001). Only 6%, (12 patients, 10 out- and 2 inpatients) discontinued treatment at 1 year of follow-up; Kaplan-Meier curves demonstrated significant differences in PP6M treatment discontinuation between out- and inpatients (p=0.012). The main reason for discontinuation was lack of adherence (5 patients) while only 1 patient stopped treatment due to tolerability issues (extrapyramidal side effects).

Conclusions: This is the first mirror-image study in patients with schizophrenia treated with PP6M in real-world settings showing very high treatment persistence, reduced hospital admissions compared to previous LAIs and no major safety concerns. Our findings suggest that six-monthly treatment with a long-acting antipsychotic may confer additional benefits in the management of schizophrenia. Nonetheless, we were unable to determine the precise changes in symptoms. Therefore, future studies are needed to truly establish the role of PP6M.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913845PMC
http://dx.doi.org/10.3389/fpsyt.2025.1540213DOI Listing

Publication Analysis

Top Keywords

patients schizophrenia
16
hospital admissions
12
pp6m
10
patients
9
2-year mirror-image
8
benefits management
8
management schizophrenia
8
mirror-image study
8
number hospital
8
out- inpatients
8

Similar Publications

Identification and prioritization of gene sets associated with schizophrenia risk by network analysis.

Psychopharmacology (Berl)

September 2025

Institute of Cardiovascular Research, Sleep Medical Center, Department of Psychiatry, Fundamental and Clinical Research on Mental Disorders Key Laboratory of Luzhou, Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan Province, 646000, China.

Rationale: Genome-wide association studies (GWASs) are used to identify genetic variants for association with schizophrenia (SCZ) risk; however, each GWAS can only reveal a small fraction of this association.

Objectives: This study systematically analyzed multiple GWAS data sets to identify gene subnetwork and pathways associated with SCZ.

Methods: We identified gene subnetwork using dmGWAS program by combining SCZ GWASs and a human interaction network, performed gene-set analysis to test the association of gene subnetwork with clinical symptom scores and disease state, meanwhile, conducted spatiotemporal and tissue-specific expression patterns and cell-type-specific analysis of genes in the subnetwork.

View Article and Find Full Text PDF

We examined the effects of combining cognitive training plus aerobic exercise versus cognitive training alone on positive symptoms in recent-onset schizophrenia patients. Sixty-eight participants were randomly assigned to Cognitive Training plus Exercise (CT&E,  = 37) or Cognitive Training alone (CT,  = 31). All participants were also randomly assigned to either oral risperidone or paliperidone palmitate (PP1M) in a concurrent antipsychotic medication study.

View Article and Find Full Text PDF

Background: It is known that disorders of mental activity in schizophrenia patients may be caused by an impairment in the actualization of past experience during anticipation (prediction), which leads to impairment in constructing predictions, comparing incoming sensory information with the predictions, and updating the predictions. Previous studies have shown that the probability of an expected event affects the components of event-related potentials in mentally healthy individuals. However, it has not yet been studied how changes in the probability of an expected stimulus influence the behavior of individuals with schizophrenia and their event-related potential measures.

View Article and Find Full Text PDF

Background: Functional and structural studies of the brain highlight the importance of white matter alterations in schizophrenia. However, molecular studies of the alterations associated with the disease remain insufficient.

Aim: To study the lipidome and transcriptome composition of the corpus callosum in schizophrenia, including analyzing a larger number of biochemical lipid compounds and their spatial distribution in brain sections, and corpus callosum transcriptome data.

View Article and Find Full Text PDF

Predicting Physical Aggression among Schizophrenia Patients in Rural Communities of Southwestern China.

Alpha Psychiatry

August 2025

The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, 610036 Chengdu, Sichuan, China.

Objective: Physical aggression in schizophrenia patients carries significant societal implications. Previous studies on aggression prediction have primarily focused on hospitalized patients, overlooking specific rural community contexts in China. This study investigated multidimensional predictive factors to develop and validate a predictive model for predicting physical aggression in schizophrenia patients in rural communities in southwestern China.

View Article and Find Full Text PDF